ClinicaliQ Trial Snapshot
- A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves’ Disease — Recruiting • Phase II • NCT06984627.
- A trial testing whether rilzabrutinib improves Graves' disease symptoms and safety over 16 weeks in two dose groups.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years or older. Study details include: * Screening period (up to 4 weeks). * Treatment period (up to 16 weeks). * Follow-up period (4 weeks). The number of visits will be up to 13. Conditions: Graves' Disease Interventions: Rilzabrutinib dose 1, Rilzabrutinib dose 2 Lead Sponsor: Sanofi Planned Enrollment: 30 participants